Defensins

Overview

Defensins are a large family of small (2-5 kDa), cationic, cysteine-rich antimicrobial peptides that form a critical component of the innate immune system in humans and virtually all other vertebrates and many invertebrates. They are among the most ancient and conserved antimicrobial molecules in biology, with evolutionary origins predating the adaptive immune system by hundreds of millions of years.

In humans, defensins are produced by neutrophils, macrophages, epithelial cells of the skin, respiratory tract, gastrointestinal tract, and urogenital tract. They provide a rapid, broad-spectrum first line of defense against invading pathogens while simultaneously orchestrating broader immune responses through immunomodulatory activities.

Classification

Human defensins are classified into two subfamilies based on the pattern of their disulfide bonds:

Alpha-Defensins

Six alpha-defensins have been identified in humans:

Human Neutrophil Peptides (HNP-1 through HNP-4):

• Stored in azurophil granules of neutrophils at concentrations up to 10 mg/mL
• Released during degranulation at sites of infection
• HNP-1, HNP-2, and HNP-3 differ by only a single N-terminal amino acid
• HNP-4 is the most potent antimicrobial of the group but is expressed at lower levels

Human Defensins 5 and 6 (HD-5 and HD-6):

• Produced by Paneth cells at the base of intestinal crypts in the small intestine
• Secreted into the intestinal lumen upon microbial stimulation
• HD-5 has broad antimicrobial activity; HD-6 uniquely forms nanonets that physically trap bacteria
• Critical for maintaining intestinal microbial homeostasis and preventing bacterial translocation within the gut microbiome

Beta-Defensins

Over 40 beta-defensin genes have been identified in the human genome, though only a few have been well characterized:

hBD-1 (Human Beta-Defensin 1):

• Constitutively expressed in epithelial tissues (skin, respiratory tract, urogenital tract)
• Provides basal antimicrobial protection
• Expression is not significantly increased by infection or inflammation

hBD-2:

• Inducible by bacterial products (LPS), inflammatory cytokines (IL-1beta, TNF-alpha), and pathogen contact
• First inducible human antimicrobial peptide identified (1997)
• Active against gram-negative bacteria and Candida

hBD-3:

• Inducible; has the broadest antimicrobial spectrum of the beta-defensins
• Active against gram-positive bacteria including MRSA, gram-negative bacteria, and fungi
• Unique among defensins in maintaining activity at physiological salt concentrations
• Expression induced by pathogen contact and inflammatory signaling

hBD-4:

• Most salt-resistant human beta-defensin
• Expressed in testes, respiratory epithelium, and other tissues
• Less well characterized than hBD-1 through hBD-3

Structure

The Defensin Fold

All defensins share a characteristic three-dimensional structure stabilized by three intramolecular disulfide bonds between six conserved cysteine residues. This cyclization-mediated structure creates a compact, rigid framework that is remarkably resistant to proteolytic degradation — an example of how protein folding shapes biological activity.

Alpha-defensin disulfide connectivity: Cys1-Cys6, Cys2-Cys4, Cys3-Cys5

Beta-defensin disulfide connectivity: Cys1-Cys5, Cys2-Cys4, Cys3-Cys6

Despite the different disulfide patterns, both subfamilies adopt a similar overall three-dimensional fold: a triple-stranded antiparallel beta-sheet with a characteristic amphipathic character — one face of the molecule is hydrophobic and one is cationic.

Structure-Activity Relationships

• The cationic charge (typically +2 to +9) enables electrostatic attraction to negatively charged bacterial membranes
• The amphipathic structure allows insertion into and disruption of lipid bilayers
• The disulfide-stabilized fold provides exceptional protease resistance
• Removal of disulfide bonds generally reduces antimicrobial potency (though linear analogs of some defensins retain partial activity)

Antimicrobial Mechanisms

Membrane Disruption

The primary antimicrobial mechanism. Defensins interact with bacterial membranes through a multi-step process:

1. Electrostatic attraction — Cationic defensins are drawn to the negatively charged outer membrane of bacteria (lipopolysaccharide in gram-negatives, teichoic acids in gram-positives)
2. Membrane insertion — The hydrophobic face inserts into the lipid bilayer
3. Pore formation or membrane disruption — At sufficient concentration, defensins form pores or destabilize the membrane, causing loss of membrane potential and cell death
4. Selectivity — Mammalian cell membranes are enriched in cholesterol and zwitterionic phospholipids, giving them a more neutral charge that reduces defensin affinity and provides selectivity for bacterial targets

Intracellular Targets

Some defensins penetrate bacterial membranes without immediate lysis and act on intracellular targets:

• Inhibition of DNA and RNA synthesis
• Disruption of protein folding
• Interference with cell wall synthesis

Anti-Biofilm Activity

Several defensins can disrupt established bacterial biofilms or prevent biofilm formation, a property of particular clinical interest given that biofilm-associated infections are notoriously resistant to conventional antibiotics.

Antiviral Activity

Defensins demonstrate activity against enveloped viruses including:

• HIV-1 (HNP-1 through HNP-3 block viral entry and inhibit replication)
• Herpes simplex virus
• Influenza virus
• SARS-CoV-2 (hBD-2 and HNP-1 show in vitro antiviral activity)

Mechanisms include direct virion disruption, blocking of viral attachment, and interference with viral replication machinery.

Immunomodulatory Functions

Beyond direct killing, defensins serve as critical bridges between innate and adaptive immunity:

Chemotaxis

• HNP-1/2 recruit monocytes, T-cells, and dendritic cells to infection sites
• hBD-2 is chemotactic for dendritic cells and memory T-cells through CCR6 receptor binding
• hBD-3 recruits monocytes and macrophages

Immune Cell Activation

• Defensins activate dendritic cells, promoting antigen presentation
• They stimulate cytokine production including IL-8, IL-6, and IL-10
• They modulate macrophage polarization toward pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes

Wound Healing

Defensins promote wound healing through:

• Stimulation of keratinocyte and fibroblast migration
• Promotion of angiogenesis
• Enhancement of epithelial barrier restoration
• Regulation of extracellular matrix remodeling

Clinical Significance

Defensin Deficiency

Reduced defensin expression or function is associated with increased infection susceptibility:

• Decreased alpha-defensin levels correlate with susceptibility to lung infections
• Reduced Paneth cell defensin expression is observed in ileal Crohn's disease
• Genetic variants in beta-defensin genes are associated with susceptibility to psoriasis, atopic dermatitis, and Crohn's disease

Defensin Excess

Overexpression of defensins contributes to inflammatory pathology:

• Elevated HNP levels in bronchoalveolar fluid of ARDS patients
• Increased hBD-2 in psoriatic skin lesions
• Elevated defensin levels in inflammatory bowel disease

Therapeutic Development

Defensins and defensin-derived compounds are being developed for:

• Topical antimicrobial agents — Wound dressings and surgical site prophylaxis
• Anti-infective therapeutics — Particularly for multidrug-resistant organisms
• Peptide vaccine adjuvants — Leveraging their ability to activate dendritic cells and link innate to adaptive immunity
• Anti-inflammatory agents — Selective modulation of immune responses

Brilacidin, a synthetic defensin mimetic, has advanced to Phase II clinical trials for acute bacterial skin infections, demonstrating the feasibility of translating defensin biology into therapeutic applications.

Dosing Protocols

As endogenous antimicrobial peptides, defensins are not typically administered exogenously in clinical practice. They are primarily studied as biomarkers of innate immune activation and as templates for novel antimicrobial drug design. Clinical development of defensin-based therapeutics faces challenges including proteolytic instability, potential cytotoxicity at therapeutic concentrations, salt sensitivity that reduces antimicrobial activity in physiological conditions, and manufacturing complexity due to multiple disulfide bonds.

Challenges and Limitations

• Salt sensitivity — Many defensins lose activity at physiological salt concentrations (hBD-3 is a notable exception)
• Serum binding — Plasma proteins can sequester defensins and reduce effective concentrations
• Manufacturing complexity — The three disulfide bonds require correct folding for full activity, complicating recombinant production
• Toxicity — At high concentrations, defensins can damage host cells, narrowing the therapeutic index
• Resistance mechanisms — Some bacteria modify their membrane charge or produce proteases that degrade defensins

Despite these challenges, defensins remain one of the most promising families of natural antimicrobial compounds for addressing the growing crisis of antibiotic resistance.